LNP Summit 2025: Navigating LNP IP Challenges & Freedom to Operate
Presented at our LNP Summit Boston – Sept 9 2025
by Dan Shores, Partner, Rothwell Figg
Dan Shores delivers a practical and thought‑provoking deep dive into the Intellectual Property (IP) landscape surrounding lipid nanoparticle (LNP) technologies. His session covers:
🔹 Key considerations for evaluating freedom to operate (FTO)
🔹 How IP challenges evolve from early development through clinical and commercial stages
🔹 Important factors to understand when developing LNP formulations and novel ionizable lipids
🔹 Strategies for anticipating potential IP hurdles and positioning innovations effectively
Access LNP Video Now
Related Resources
Want to find out more?
Get in touch with our team of experts to explore bespoke end-to-end CDMO support of your complete drug lifecycle
at any scale.